ANTI-OBESITY DRUG MARKET ANALYSIS

Anti-Obesity Drug Market, By Mechanism of Action (Peripherally Acting Anti-Obesity Drugs and Centrally Acting Anti-obesity Drugs), By Prescription/Non- prescription (Prescription Drugs and OTC Drugs), And by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Published In : Apr 2023
Code : CMI2824
Pages :170
Formats :
Excel and PDF
Industry : Pharmaceutical

Market News

In June 2021, the US Food and Drug Administration (FDA) approved a 2.4 mg/week subcutaneous dose of the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide (Wegovy, developed by Novo Nordisk) for weight loss (obesity).

In January 2020, Novo Nordisk AS, a global healthcare company, signed a partnership with the startup Fauna Bio, a Biotechnology company, to identify new therapeutic approaches to obesity by studying the molecules and pathways that regulate metabolism in hibernating animals.